Empowered Funds LLC Takes $2.26 Million Position in Inspire Medical Systems, Inc. $INSP

Key Points

• Empowered Funds LLC acquired 50,657 shares of Inspire Medical Systems worth approximately $2.26 million, representing a 0.18% stake. Institutional investors collectively own 94.91% of the company.
• Inspire Medical Systems reported quarterly EPS of $0.14, beating estimates of a $0.24 loss, while revenue of $200.58 million exceeded forecasts but declined 7.6% year over year.
• Shares recently traded at $63.20, up 2.7%, while analysts maintain a consensus “Hold” rating with an average price target of $66.19; recommendations range from a $39 underperform target to a $75 target.

Empowered Funds LLC acquired a new stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 50,657 shares of the company's stock, valued at approximately $2,260,000. Empowered Funds LLC owned 0.18% of Inspire Medical Systems as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in INSP. Royal Bank of Canada lifted its position in shares of Inspire Medical Systems by 16.0% during the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company's stock valued at $5,220,000 after acquiring an additional 4,528 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of Inspire Medical Systems in the 1st quarter worth approximately $524,000. Goldman Sachs Group Inc. increased its stake in Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company's stock valued at $8,190,000 after purchasing an additional 18,857 shares in the last quarter. Marshall Wace LLP increased its stake in Inspire Medical Systems by 3.8% in the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company's stock valued at $2,064,000 after purchasing an additional 577 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in Inspire Medical Systems during the second quarter worth $931,000. Hedge funds and other institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Trading Up 2.7%

NYSE:INSP opened at $63.20 on Thursday. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 13.68, a price-to-earnings-growth ratio of 4.68 and a beta of 0.70. The company's 50-day moving average is $54.33 and its two-hundred day moving average is $52.35. Inspire Medical Systems, Inc. has a 12-month low of $38.91 and a 12-month high of $147.03.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company's quarterly revenue was down 7.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities research analysts forecast that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider owned 18,985 shares of the company's stock, valued at $1,130,556.75. This represents a 4.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 2.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on INSP. Bank of America downgraded Inspire Medical Systems from a "neutral" rating to an "underperform" rating and set a $39.00 target price on the stock. in a research report on Friday, May 22nd. Weiss Ratings upgraded shares of Inspire Medical Systems from a "sell (d)" rating to a "sell (d+)" rating in a report on Wednesday, August 19th. Summit Redstone set a $39.00 target price on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $60.00 price target on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Finally, Stifel Nicolaus set a $75.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $66.19.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source